Gaboxadol for reducing risk of suicide and rapid relief of depression
AssigneeCertego Therapeutics
InventorsPavel Osten, Kristin Baldwin
Life of this patent
Estimating the term…
Abstract
Methods and compositions are disclosed for rapidly reducing the risk of suicide in patients suffering from acute suicidality and rapidly relieving mood symptoms in major depression and treatment-resistant depression using a novel therapeutic regimen comprising a single or intermittent administration of a high dose of gaboxadol, or a pharmaceutically acceptable salt thereof, to the subject in need thereof.
Claims25
1-24. (canceled)
A method of treating a human patient with depression, said method comprising the following steps in the order stated:
- (a) orally administering to the human patient gaboxadol or a pharmaceutically acceptable salt thereof, followed by a wash-out period of 3 or more days during which no gaboxadol or pharmaceutically acceptable salt thereof is administered to the patient;
- and
- (b) orally administering gaboxadol or a pharmaceutically acceptable salt thereof after said wash-out period.
A method of reducing risk of suicide in a human patient, said method comprising the following steps in the order stated:
- (a) orally administering to the patient gaboxadol or a pharmaceutically acceptable salt thereof, followed by a wash-out period of 3 or more days during which no gaboxadol or pharmaceutically acceptable salt thereof is administered to the patient;
- and
- (b) orally administering gaboxadol or a pharmaceutically acceptable salt thereof after said wash-out period.
Dependencies are inferred from the claim text.